Logo

Investment Bank Downgrades Thermo Electron Despite Growth Guidance

Dec 23, 2005

NEW YORK, Dec. 23 (GenomeWeb News) - An investment bank today downgraded its outlook for Thermo Electron despite the revenue growth expected by the company in 2006.

 

Needham & Co cut Thermo Electron's shares to "Buy" from "Strong Buy."

 

As reported in yesterday's GenomeWeb News, Thermo Electron expects total revenue for 2006 to grow 7 percent, to between $2.78 billion and $2.83 billion. According to Reuters Estimates, the company's guidance misses Wall Street's sales expectations of $2.89 billion.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.